Clinical Trial Update: Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing the safety and efficacy of a regimen combining BTK inhibitor with anti-CD19 CAR-T cells for relapsed/refractory B-cell non-Ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• BTK inhibitor + anti-CD19 CAR-T cells regimen

Snippet

Sponsor: The Affiliated Hospital of Xuzhou Medical University | Conditions: B-cell Non Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN